A detailed history of Redmile Group, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 642,229 shares of IMVT stock, worth $17.7 Million. This represents 1.16% of its overall portfolio holdings.

Number of Shares
642,229
Previous 720,177 10.82%
Holding current value
$17.7 Million
Previous $19 Million 7.07%
% of portfolio
1.16%
Previous 1.24%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$27.51 - $27.51 $2.14 Million - $2.14 Million
-77,948 Reduced 10.82%
642,229 $17.7 Million
Q2 2024

Aug 14, 2024

SELL
$25.1 - $31.61 $6.26 Million - $7.88 Million
-249,444 Reduced 25.73%
720,177 $19 Million
Q1 2024

May 15, 2024

SELL
$30.27 - $43.79 $225,541 - $326,279
-7,451 Reduced 0.76%
969,621 $31.3 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $29.6 Million - $41.7 Million
-944,080 Reduced 49.14%
977,072 $41.2 Million
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $8.58 Million - $14.3 Million
604,121 Added 45.87%
1,921,152 $36.4 Million
Q1 2023

May 15, 2023

BUY
$15.27 - $19.72 $3.5 Million - $4.51 Million
228,900 Added 21.04%
1,317,031 $20.4 Million
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $7.17 Million - $19.3 Million
1,088,131 New
1,088,131 $19.3 Million
Q4 2020

Feb 16, 2021

SELL
$36.36 - $52.71 $4.4 Million - $6.37 Million
-120,940 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$22.61 - $38.9 $10.8 Million - $18.6 Million
-479,060 Reduced 79.84%
120,940 $4.26 Million
Q2 2020

Aug 14, 2020

BUY
$13.87 - $28.44 $8.32 Million - $17.1 Million
600,000 New
600,000 $14.6 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.